| Name | Title | Contact Details |
|---|---|---|
Frederick Porter |
Chief Technical Officer | Profile |
Refuge is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient`s body.
The THOR Group is a Manhattan Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
jCyte is a clinical-stage company focused on the application of progenitor cell-based technology in retinal diseases. The Company`s allogeneic product candidate, jCell, is delivered by simple intravitreal injection without the need for surgery or immune suppression. jCyte has completed a phase 1/2a, phase 1/2a extension and phase 2b clinical trials testing jCell in patients with Retinitis Pigmentosa.
Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease.
Biothera is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.